Vilket är priset för Heat Biologics, Inc. (HTBX)

Priset för Heat Biologics, Inc. (HTBX) är $2.38

Vilket är marknadsvärdet för Heat Biologics, Inc. (HTBX)

Marknadsvärdet för Heat Biologics, Inc. (HTBX) är $61.07M

Heat Biologics, Inc. (HTBX) Vinst

Heat Biologics, Inc. is an integrated biopharmaceutical company focused on creating immune-modulating therapies and vaccines. The firm's primary goal is to harness the immune system to fight a variety of illnesses, including both cancerous growths and infectious diseases. A cornerstone of their approach is the gp96 platform, which comprises two key components: ImPACT, an allogenic cell-based system designed to stimulate and proliferate T-cells as an immune activator, and ComPACT, a singular product engineered to achieve both antigen-driven T-cell activation and specific co-stimulation simultaneously. Their development pipeline includes several clinical-stage assets. HS-110 has finished enrolling patients for its Phase II trial targeting advanced non-small cell lung cancer, while HS-130 is currently in a Phase I clinical trial for advanced solid tumors. Furthermore, PTX-35, a novel T-cell co-stimulator agonist antibody that acts on DR3/TNFRSF25, is being evaluated in a Phase I clinical trial for diverse immunotherapy applications. The company is also advancing a COVID-19 vaccine, which is currently in the preclinical stage. Heat Biologics, Inc. has partnered with Dr. James Shapiro at the University of Alberta to develop a surrogate mouse version of PTX-35. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.

År	Vinst	Ändra
Inte tillräckligt med data för de angivna datumen.

År

Vinst

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	Vinst	Skillnad i vinst	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Moderna, Inc. MRNA.US	$-3.09B	-	US
CSL Limited CSL.AX	$1.61B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Företag

Vinst

Skillnad i vinst

Land